Evidence map›Paper›PMID 31938433›Full record

ArticleInternational journal of clinical and experimental pathology2018

Clinical significance of BCL11A expression in ER-negative and PR-negative endometrial carcinoma.

Di You, Lin Lin, Qilin Wang, Tianjin Yi, Lingjun Zhao, Maomao Li, Ping Wang

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. The Impact ofPharmacogenomics and personalized medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Di YouDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University Chengdu, Sichuan Province, China.
Lin LinDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University Chengdu, Sichuan Province, China.
Qilin WangDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University Chengdu, Sichuan Province, China.
Tianjin YiDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University Chengdu, Sichuan Province, China.
Lingjun ZhaoDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University Chengdu, Sichuan Province, China.
Maomao LiDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University Chengdu, Sichuan Province, China.
Ping WangDepartment of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University Chengdu, Sichuan Province, China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the mechanism and clinical significance of B-cell lymphoma/leukemia 11A (BCL11A) gene in the development of endometrial carcinoma (EC).

methods100 EC, 20 normal endometrium and 20 atypical hyperplasia endometrium specimens were collected from West China Second University Hospital from January 2005 to January 2015. The expression of BCL11A was detected by immunohistochemistry and its relationships with clinicopathological features and survival were analyzed.

resultsThe expression of BCL11A in ER-/PR-EC was higher than that in normal endometrium, atypical hyperplasia endometrium, and ER+/PR+EC (P < 0.001). The expression of BCL11A in EC was associated with age, menopause, EC classification, para-aortic lymph node metastasis, tumor differentiation, histological type, ER/PR expression and p53 expression (P < 0.05). The expression of BCL11A in the deceased group was significantly higher than that in the survival group (P = 0.011). Survival analysis indicated that the high expression of BCL11A was associated with low survival rate (P < 0.001).

conclusionsBCL11A may play an important role in the development of ER-/PR-EC. It may serve as a potential target for therapy and a predict factor for prognosis. It can also provide molecular basis for new EC classification.

Indexed as

BCL11AEndometrial carcinoma (EC)estrogen receptor (ER)immunohistochemistry (IHC)progesterone receptor (PR)survival analysis

Identifiers

PMID31938433
PMCPMC6958092
OpenAlexW3006684021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.